Leveraging Persuasive Technologies for Global Health: Insights Across COVID-19 Digital Contact Tracing Technologies
Communication Design Quarterly · 01.03.2026 · 14 (1) · 5-21
DOI: 10.1145/3794916.3794918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communication Design Quarterly, online erschienen am 05.05.2026. Verfasst von Yeqing Kong und 3 weiteren Autor:innen. Die Arbeit nennt 59 Literaturangaben.
Abstract (Originalsprache)
This article examines how digital contact tracing technologies for COVID-19 in Ghana, the US, China, and India function as persuasive technologies. Through comparative analysis, we investigate how each context emphasizes persuasive design strategies and how these align with national public health objectives. We propose an extended Common Interpretive Framework for Design Analysis (eCIFDA), which integrates Persuasive Systems Design with Interaction Design to map persuasive techniques to touchpoints within apps and a website. This study offers insights for technical communication scholars and practitioners seeking to strengthen the persuasive effectiveness of digital health interventions across diverse geopolitical contexts.
Zitieren
APA
Kong, Y., Agbozo, G. E., Weaver, I. R., & Ray, A. (2026). Leveraging Persuasive Technologies for Global Health: Insights Across COVID-19 Digital Contact Tracing Technologies. Communication Design Quarterly, 14(1), 5-21. https://doi.org/10.1145/3794916.3794918
Vancouver
Kong Y, Agbozo GE, Weaver IR, Ray A. Leveraging Persuasive Technologies for Global Health: Insights Across COVID-19 Digital Contact Tracing Technologies. Communication Design Quarterly. 2026;14(1):5-21. doi:10.1145/3794916.3794918
BibTeX
@article{Kong2026,
author = {Kong, Yeqing and Agbozo, G. Edzordzi and Weaver, Ian R. and Ray, Anirban},
title = {Leveraging Persuasive Technologies for Global Health: Insights Across COVID-19 Digital Contact Tracing Technologies},
journal = {Communication Design Quarterly},
year = {2026},
volume = {14},
number = {1},
pages = {5--21},
doi = {10.1145/3794916.3794918}
}
EUVIMED